[Immune checkpoint inhibition in Merkel cell carcinoma].

DISCUSSION: Checkpoint inhibition offers an effective treatment option for patients with MCC. Avelumab is currently licensed as a treatment for metastatic disease. Chemotherapy remains an option to reduce tumor load, or in the context of resistance and/or contraindications to immune checkpoint therapy. Adjuvant and neoadjuvant use of checkpoint inhibition in MCC may represent a future treatment strategy pending the results of on-going clinical trials. PMID: 31468071 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31468071?dopt=Abstract

Source: Der Hautarzt: Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete - August 31, 2019 Category: Dermatology Tags: Hautarzt Source Type: research